BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

University of California, Los Angeles (UCLA) and Sound Pharmaceuticals, Inc. Identify a Key Hearing Regeneration Protein in the Human Inner Ear


2/25/2011 7:10:26 AM

SEATTLE, Feb. 24, 2011 /PRNewswire/ -- In collaboration with scientists and clinicians from the University of California Los Angeles, scientists from Sound Pharmaceuticals have found p27Kip1 to be expressed in the adult and aged human inner ear including the auditory and vestibular sensory organs. In the adult human inner ear, the pattern of p27Kip1 expression was restricted to the nuclei of supporting cells in the organ of Corti, the sensory organ that controls hearing, and the utricle and cristae, two sensory organs that control balance. These findings are identical to what has been observed and reported in neonatal and adult rodents, further validating p27Kip1 as a key regeneration target in the deafened mammalian inner ear. The fact that p27Kip1 was expressed in the supporting cells of the aged human cochlea from patients over 80 years old suggests that p27Kip1 is still working to suppress proliferative regeneration throughout life and is an appropriate drug target to stimulate supporting cell and hair cell regeneration. These findings were presented at the 34th Annual Midwinter Meeting of the Association for Research in Otolaryngology held this week. This work was supported by the National Institute on Deafness and Other Communication Disorders and the Office of Naval Research.

SPI is developing a proprietary technology for regenerating cells within the inner ear of mammals as a means to restore auditory function to the hearing impaired or deaf. By inhibiting p27Kip1, a cyclin dependent kinase inhibitor or CKI, supporting cell and auditory hair cell regeneration is stimulated in adult mice and Guinea pigs that were previously exposed to intense noise or ototoxic drugs. This novel proliferative and regenerative ability is absent in adult mammals, resulting in permanent and often progressive sensorineural hearing loss, the most common communication disorder and neurologic disease. Current development is focused on the local injection of an inhibitor of p27Kip1 (a p27 siRNA) into the cochlea of deafened adult mammals five weeks after the establishment of permanent hearing loss. The ultimate goal of this novel CKI inhibition technology is to restore hearing to the severe or profoundly impaired.

Sound Pharmaceuticals, Inc. is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Jonathan Kil, MD, President and CEO, 206-634-2559 or visit www.soundpharma.com.

SOURCE Sound Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES